National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Vericiguat (Verquvo®). HTA ID: 21027

Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 21/06/2021
Rapid review completed 15/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vericiguat compared with the current standard of care.